Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Exclusion Criteria

• •History of any meningococcal B vaccine administration (only for groups 5 and 6);
• •Previous ascertained or suspected disease caused by N. meningitidis;
• •History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
• •Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to 38 degrees within the previous day
• •Antibiotics within 6 days prior to enrollment;
• •Any serious chronic or progressive disease;
• •Known or suspected impairment or alteration of the immune system;
• •Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.